Search

Your search keyword '"Turrini, Maria Vittoria"' showing total 6 results
Start Over Author "Turrini, Maria Vittoria"
6 results on '"Turrini, Maria Vittoria"'

3. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

Author

Mancinelli, Chiara Rosa, Scarpazza, Cristina, Cordioli, Cinzia, De Rossi, Nicola, Rasia, Sarah, Turrini, Maria Vittoria, and Capra, Ruggero

Subjects
NATALIZUMAB, MAGNETIC resonance imaging, PROGRESSIVE multifocal leukoencephalopathy
Abstract

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab, underwent magnetic resonance imaging (MRI) and clinical monitoring during washout and after ocrelizumab starting. During the first 3 months, disease reactivation was observed in five (12%) patients; 6 months after ocrelizumab starting, no further relapses were recorded, and Expanded Disability Status Scale (EDSS) remained stable in 38 (90%) patients. In conclusion, ocrelizumab could be considered a choice to mitigate the risk of disease reactivation in patients previously treated with natalizumab-EID. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

4. Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis

Author

Iannello, Andrea, primary, Rolla, Simona, additional, Maglione, Alessandro, additional, Ferrero, Giulio, additional, Bardina, Valentina, additional, Inaudi, Ilenia, additional, De Mercanti, Stefania, additional, Novelli, Francesco, additional, D'Antuono, Lucrezia, additional, Cardaropoli, Simona, additional, Todros, Tullia, additional, Turrini, Maria Vittoria, additional, Cordioli, Cinzia, additional, Puorro, Giorgia, additional, Marsili, Angela, additional, Lanzillo, Roberta, additional, Brescia Morra, Vincenzo, additional, Cordero, Francesca, additional, De Bortoli, Michele, additional, Durelli, Luca, additional, Visconti, Andrea, additional, Cutrupi, Santina, additional, and Clerico, Marinella, additional

Published
2019
Full Text
View/download PDF

5. Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis

Author

Cinzia Cordioli, Andrea Visconti, Alessandro Maglione, Vincenzo Brescia Morra, Maria Vittoria Turrini, Angela Marsili, Stefania Federica De Mercanti, Simona Rolla, Marinella Clerico, Luca Durelli, Tullia Todros, Ilenia Inaudi, Andrea Iannello, Francesco Novelli, Lucrezia D'Antuono, Santina Cutrupi, Valentina Bardina, Giorgia Puorro, Giulio Ferrero, Francesca Cordero, Roberta Lanzillo, Simona Cardaropoli, Michele De Bortoli, Iannello, Andrea, Rolla, Simona, Maglione, Alessandro, Ferrero, Giulio, Bardina, Valentina, Inaudi, Ilenia, De Mercanti, Stefania, Novelli, Francesco, D'Antuono, Lucrezia, Cardaropoli, Simona, Todros, Tullia, Turrini, Maria Vittoria, Cordioli, Cinzia, Puorro, Giorgia, Marsili, Angela, Lanzillo, Roberta, Brescia Morra, Vincenzo, Cordero, Francesca, De Bortoli, Michele, Durelli, Luca, Visconti, Andrea, Cutrupi, Santina, and Clerico, Marinella

Subjects
0301 basic medicine, Estrogen receptor, epigenetic profile, Regulatory Sequences, Nucleic Acid, multiple sclerosis, T-Lymphocytes, Regulatory, Epigenesis, Genetic, RORC, 0302 clinical medicine, RAR-related orphan receptor gamma, Immunology and Allergy, MULTIPLE SCLEROSIS, ESTROGEN RECEPTOR, EPIGENETICS, Original Research, ERα, biology, Estradiol, FOXP3, Cell Polarity, Forkhead Transcription Factors, Middle Aged, Nuclear Receptor Subfamily 1, Group F, Member 3, Healthy Volunteers, EPIGENETICS, Histone Code, Treg, Histone, multiple sclerosi, Female, pregnancy, Th17, Adult, lcsh:Immunologic diseases. Allergy, Adolescent, Pregnancy Trimester, Third, Immunology, Peripheral blood mononuclear cell, Polymorphism, Single Nucleotide, 03 medical and health sciences, Young Adult, Multiple Sclerosis, Relapsing-Remitting, medicine, Humans, Epigenetics, ESTROGEN RECEPTOR, Analysis of Variance, business.industry, Multiple sclerosis, Estrogen Receptor alpha, medicine.disease, Chromatin Assembly and Disassembly, 030104 developmental biology, biology.protein, Th17 Cells, business, Transcriptome, lcsh:RC581-607, Estrogen receptor alpha, 030215 immunology
Abstract

Increasing evidence supports the anti-inflammatory role of estrogens in Multiple Sclerosis (MS), originating from the observation of reduction in relapse rates among women with MS during pregnancy, but the molecular mechanisms are still not completely understood. Using an integrative data analysis, we identified T helper (Th) 17 and T regulatory (Treg) cell-type-specific regulatory regions (CSR) regulated by estrogen receptor alpha (ERα). These CSRs were validated in polarized Th17 from healthy donors (HD) and in peripheral blood mononuclear cells, Th17 and Treg cells from relapsing remitting (RR) MS patients and HD during pregnancy. 17β-estradiol induces active histone marks enrichment at Forkhead Box P3 (FOXP3)-CSRs and repressive histone marks enrichment at RAR related orphan receptor C (RORC)-CSRs in polarized Th17 cells. A disease-associated epigenetic profile was found in RRMS patients during pregnancy, suggesting a FOXP3 positive regulation and a RORC negative regulation in the third trimester of pregnancy. Altogether, these data indicate that estrogens act as immunomodulatory factors on the epigenomes of CD4+ T cells in RRMS; the identified CSRs may represent potential biomarkers for monitoring disease progression or new potential therapeutic targets.

Published
2019

6. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

Author

Mancinelli CR, Scarpazza C, Cordioli C, De Rossi N, Rasia S, Turrini MV, and Capra R

Subjects
Antibodies, Monoclonal, Humanized, Humans, Immunologic Factors adverse effects, Natalizumab adverse effects, Retrospective Studies, Leukoencephalopathy, Progressive Multifocal chemically induced, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab, underwent magnetic resonance imaging (MRI) and clinical monitoring during washout and after ocrelizumab starting. During the first 3 months, disease reactivation was observed in five (12%) patients; 6 months after ocrelizumab starting, no further relapses were recorded, and Expanded Disability Status Scale (EDSS) remained stable in 38 (90%) patients. In conclusion, ocrelizumab could be considered a choice to mitigate the risk of disease reactivation in patients previously treated with natalizumab-EID.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results